Prevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en España. Estudio DYSIS-España

2007, European guidelines on cardiovascular disease prevention in clinical practice, Eur Heart J., 28, 2375, 10.1093/eurheartj/ehm316 Cordero, 2009, Diferences in medical treatment of chronic coronary heart disease patients according to medical specialities, Cardiovasc Ther., 27, 173, 10.1111/j.1755-5922.2009.00093.x Gabriel, 2008, Prevalencia, distribución y variabilidad geográfica de los principales factores de riesgo cardiovascular en España. Análisis agrupado de datos individuales de estudios epidemiológicos poblacionales: estudio ERICE, Rev Esp Cardiol., 61, 1030, 10.1157/13126043 Haffner, 2003, Epidemic obesity and the metabolic syndrome, Circulation., 108, 1541, 10.1161/01.CIR.0000088845.17586.EC Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet., 364, 937, 10.1016/S0140-6736(04)17018-9 Medrano, 2007, Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española, Rev Esp Cardiol., 60, 1250, 10.1157/13113930 Brunzell, 2008, Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation, J Am Coll Cardiol., 51, 1512, 10.1016/j.jacc.2008.02.034 Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet., 366, 1267, 10.1016/S0140-6736(05)67394-1 Lee, 2007, Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets, Heart., 93, 559, 10.1136/hrt.2005.066050 2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 2002, Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies, Circulation., 79, 8, 10.1161/01.CIR.79.1.8 Turner, 1998, Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS), BMJ., 316, 823, 10.1136/bmj.316.7134.823 Cea-Calvo, 2009, Prevalence of low HLD cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS Study, Int J Clin Prac., 63, 71, 10.1111/j.1742-1241.2008.01902.x González-Juanatey, 2008, Impacto pronóstico de la localización de la enfermedad aterosclerosa previa en pacientes diabéticos. Estudio Barbanza-Diabetes, Rev Esp Cardiol., 61, 1168, 10.1157/13127848 Gitt, 2009, High prevalence of dyslipidemia in 18,574 patients treated with statins in Europe and Canada: Results of the dyslipidemia international study, Eur Heart J., 30, 303 Magliano, 2006, How to best define the metabolic syndrome, Ann Med., 38, 34, 10.1080/07853890500300311 Grant, 2007, Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction, Diabetes Care., 30, 479, 10.2337/dc06-1961 Goff, 2006, Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium, Circulation., 113, 647, 10.1161/CIRCULATIONAHA.105.552737 Daly, 2006, The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina, Eur Heart J., 27, 1298, 10.1093/eurheartj/ehl005 Nichols, 2007, Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update, Am Heart J., 154, 554, 10.1016/j.ahj.2007.04.037 Assmann, 2006, Eur J Cardiovasc Prev Rehabil., 13, 776, 10.1097/01.hjr.0000189805.76482.6e Persell, 2006, Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia, J Gen Intern Med., 21, 171, 10.1007/s11606-006-0253-2 Ose, 2006, Lipid management and cholesterol goal attainment in Norway, Am J Cardiovasc Drugs., 6, 121, 10.2165/00129784-200606020-00006 Ghandehari, 2008, Prevalence and extent of dyslipidemia and recommended lipid levels in US with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004, Am Heart J., 156, 112, 10.1016/j.ahj.2008.03.005 NCEP-ATP III Guidelines At-A-Glance Quick Desk Reference. Disponible en: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study), Am J Cardiol., 81, 582, 10.1016/S0002-9149(97)00965-X Leitersdorf, 2001, Cholesterol absorption inhibition: filling an unmet need in lipid lowering management, Eur Heart J Suppl., 3, E17, 10.1016/S1520-765X(01)90108-7 Sharrett, 2001, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study, Circulation, 104, 1108, 10.1161/hc3501.095214 Stampfer, 1991, A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction, N Engl J Med., 325, 373, 10.1056/NEJM199108083250601 Assmann, 1992, Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study, Am J Cardiol., 70, 733, 10.1016/0002-9149(92)90550-I Assmann, 1996, High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis., 124, S11, 10.1016/0021-9150(96)05852-2 Wild, 2008, Time to rethink high-density lipoprotein?, Heart., 94, 692, 10.1136/hrt.2007.126326 Ninomiya, 2004, Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey, Circulation., 109, 42, 10.1161/01.CIR.0000108926.04022.0C Alsheikh-Ali, 2007, Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol, Am J Cardiol., 100, 1499, 10.1016/j.amjcard.2007.06.058 Gitt, 2009, Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry, Eur J Cardiovasc Prev Rehabil., 16, 438, 10.1097/HJR.0b013e32832a4e25 Yan, 2006, Contemporary management of dyslipidemia in high-risk patients: targets still not met, Am J Med., 119, 676, 10.1016/j.amjmed.2005.11.015 Pearson, 2000, The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals, Arch Intern Med., 160, 459, 10.1001/archinte.160.4.459 Mosca, 2005, Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting, Circulation., 111, 488, 10.1161/01.CIR.0000153859.66086.85 Davidson, 2005, Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations, Am J Cardiol., 96, 556, 10.1016/j.amjcard.2005.04.019